Loveleen Bansi

Summary

Affiliation: University College London
Country: UK

Publications

  1. doi request reprint Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?
    Loveleen K Bansi
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Hampstead Campus, Rowland Hill Street, London, NW3 2PF, UK
    AIDS 22:349-56. 2008
  2. ncbi request reprint Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART)
    Loveleen Bansi
    HIV Epidemiology nad Biostatistics Group, Research Department of Infection and Population Health, Division of Population Health, Hampstead Campus, University College Medical School, University College London, Rowland Street, NW3 2PF, London, United Kingdom
    J Acquir Immune Defic Syndr 53:633-9. 2010
  3. doi request reprint Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations
    L Bansi
    UCL Medical School, Royal Free Campus, London, UK
    HIV Med 11:432-8. 2010
  4. doi request reprint Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study
    Loveleen Bansi
    Research Department of Infection and Population Health, University College London Medical School, London, UK
    J Acquir Immune Defic Syndr 52:391-6. 2009
  5. doi request reprint Virological response to initial antiretroviral regimens containing abacavir or tenofovir
    Loveleen Bansi
    Research Department of Infection and Population Health, University College Medical School, Royal Free Campus, London, United Kingdom
    J Infect Dis 200:710-4. 2009
  6. doi request reprint Data linkage reduces loss to follow-up in an observational HIV cohort study
    Teresa Hill
    Research Department of Infection and Population Health, UCL Medical School, London, UK
    J Clin Epidemiol 63:1101-9. 2010
  7. ncbi request reprint Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone
    Laura Waters
    Department of GU HIV Medicine, Mortimer Market Centre, London, UK
    Antivir Ther 18:213-9. 2013
  8. pmc Factors influencing lopinavir and atazanavir plasma concentration
    Wolfgang Stöhr
    MRC Clinical Trials Unit, London, UK
    J Antimicrob Chemother 65:129-37. 2010
  9. ncbi request reprint Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study
    Andrew N Phillips
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Lancet 370:1923-8. 2007
  10. doi request reprint Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study
    Tristan J Barber
    St Stephen s AIDS Trust Clinical Trials Unit, Chelsea and Westminster NHS Foundation Trust, London, UK
    Antivir Ther 16:805-14. 2011

Collaborators

Detail Information

Publications25

  1. doi request reprint Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?
    Loveleen K Bansi
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Hampstead Campus, Rowland Hill Street, London, NW3 2PF, UK
    AIDS 22:349-56. 2008
    ..We investigated whether previous treatment interruptions are associated with a raised risk of viral rebound in individuals who have attained virological suppression...
  2. ncbi request reprint Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART)
    Loveleen Bansi
    HIV Epidemiology nad Biostatistics Group, Research Department of Infection and Population Health, Division of Population Health, Hampstead Campus, University College Medical School, University College London, Rowland Street, NW3 2PF, London, United Kingdom
    J Acquir Immune Defic Syndr 53:633-9. 2010
    ..The study aim was to determine how resistance testing influences outcome of first-line highly active antiretroviral therapy (HAART) in routine practice in the United Kingdom...
  3. doi request reprint Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations
    L Bansi
    UCL Medical School, Royal Free Campus, London, UK
    HIV Med 11:432-8. 2010
    ..Effective antiretroviral therapy (ART) has transformed the care of people with HIV, but it is important to monitor time trends in indicators of treatment success and antic future changes...
  4. doi request reprint Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study
    Loveleen Bansi
    Research Department of Infection and Population Health, University College London Medical School, London, UK
    J Acquir Immune Defic Syndr 52:391-6. 2009
    ..However, the definition of an ALT flare is arbitrary and the extent to which such increases represent normal fluctuations has not been explored...
  5. doi request reprint Virological response to initial antiretroviral regimens containing abacavir or tenofovir
    Loveleen Bansi
    Research Department of Infection and Population Health, University College Medical School, Royal Free Campus, London, United Kingdom
    J Infect Dis 200:710-4. 2009
    ..88 for the interaction between pre-HAART viral load and nucleoside started). Likewise, there was no difference in rates of virological failure between the 2 drugs at 24-48 weeks after starting HAART...
  6. doi request reprint Data linkage reduces loss to follow-up in an observational HIV cohort study
    Teresa Hill
    Research Department of Infection and Population Health, UCL Medical School, London, UK
    J Clin Epidemiol 63:1101-9. 2010
    ..To ascertain the degree of loss to follow-up in a cohort and to identify its predictors...
  7. ncbi request reprint Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone
    Laura Waters
    Department of GU HIV Medicine, Mortimer Market Centre, London, UK
    Antivir Ther 18:213-9. 2013
    ..We investigated the effect of an NRTI backbone in individuals receiving Pl/r after failing NNRTI-based combined antiretroviral therapy...
  8. pmc Factors influencing lopinavir and atazanavir plasma concentration
    Wolfgang Stöhr
    MRC Clinical Trials Unit, London, UK
    J Antimicrob Chemother 65:129-37. 2010
    ..The aim of this study was to evaluate which demographic factors and concomitant drugs are associated with lopinavir and atazanavir plasma concentration...
  9. ncbi request reprint Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study
    Andrew N Phillips
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Lancet 370:1923-8. 2007
    ..We estimated the proportion of patients who had extensive triple-class failure during long-term follow-up and examined characteristics associated with an increased rate of failure...
  10. doi request reprint Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study
    Tristan J Barber
    St Stephen s AIDS Trust Clinical Trials Unit, Chelsea and Westminster NHS Foundation Trust, London, UK
    Antivir Ther 16:805-14. 2011
    ..We analysed the influence of gender on use and outcomes of first-line HAART in a UK cohort...
  11. doi request reprint Biomarkers to monitor safety in people on art and risk of mortality
    Loveleen Bansi
    UCL Medical School, Royal Free Campus, London, UK
    J Acquir Immune Defic Syndr 60:51-8. 2012
    ..Using time-updated laboratory measurements, we use several methods to derive a score that can be used to identify individuals at high risk of mortality...
  12. doi request reprint Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study
    R J C Gilson
    Centre for Sexual Health and HIV Research, Research Department of Infection and Population Health, University College London, The Mortimer Market Centre, Camden Primary Care Trust, London, UK
    HIV Med 11:152-60. 2010
    ..This study was designed to determine the incidence of a discordant response at two time-points, soon after 6 months and at 12 months, and to determine the relationship with clinical outcomes...
  13. doi request reprint HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era
    Lucy Garvey
    Clinical Trials Centre, Winston Churchill Wing, St Mary s Hospital, London, W2 1NY, UK
    Eur J Neurol 18:527-34. 2011
    ..Data describing the incidence and survival of HIV-related central nervous system diseases (CNS-D) in recent years are sparse...
  14. pmc Hepatitis B virus infection in HIV-positive individuals in the UK collaborative HIV cohort (UK CHIC) study
    Huw Price
    Centre for Sexual Health and HIV Research, Research Department of Infection and Population Health, University College London, London, United Kingdom
    PLoS ONE 7:e49314. 2012
    ..This study aimed to determine the prevalence and incidence of HBV in the UK CHIC Study, a multicentre observational cohort...
  15. doi request reprint Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor
    Tristan J Barber
    Medical Research Council Clinical Trials Unit, St Stephen s Centre, Chelsea and Westminster Hospital, 125 Kingsway, London, UK
    J Antimicrob Chemother 67:995-1000. 2012
    ..Scarce data exist from long-term cohorts on resistance incidence or mutational patterns emerging to different PIs...
  16. doi request reprint Late diagnosis in the HAART era: proposed common definitions and associations with mortality
    Caroline A Sabin
    Research Department of Infection and Population Health, UCL Medical School, London, UK
    AIDS 24:723-7. 2010
    ....
  17. ncbi request reprint Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication
    Wolfgang Stöhr
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 13:675-85. 2008
    ..The aim of this study was to examine factors influencing plasma concentration of efavirenz and nevirapine...
  18. doi request reprint The impact of HIV drug resistance testing on changes to treatment
    Loveleen Bansi
    Research Department of Infection and Population Health, UCL Medical School, UK
    AIDS 25:603-10. 2011
    ..We investigate changes made to therapy after a resistance test result and identify factors associated with switching regimen...
  19. pmc CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK
    Mark Bower
    Research Department of Infection and Population Health, Division of Population Health, UCL Medical School, Royal Free Campus, Rowland Hill Street, London, NW3 2PF, UK
    Haematologica 94:875-80. 2009
    ..Earlier highly active anti-retroviral therapy initiation and wider access to HIV testing is advocated to reduce the risk of systemic non-Hodgkin's lymphoma...
  20. doi request reprint The effect of transmitted HIV-1 drug resistance on pre-therapy viral load
    Linda Harrison
    HIV and Infections Group, MRC Clinical Trials Unit, London, UK
    AIDS 24:1917-22. 2010
    ..Reduced replication capacity of viruses expressing drug resistant mutations implies that patients with transmitted drug resistance (TDR) could have lower HIV RNA viral load than those infected with wild-type virus...
  21. doi request reprint The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy
    C A Sabin
    Department of Primary Care and Population Science, Royal Free and UC Medical School, London, UK
    HIV Med 10:35-43. 2009
    ....
  22. pmc Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception
    Susie E Huntington
    UCL Medical School, Royal Free Campus, UK
    AIDS 25:1647-55. 2011
    ....
  23. doi request reprint Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone
    Laura Waters
    Department of GU HIV Medicine, Mortimer Market Centre, London, UK
    Antivir Ther 18:213-9. 2013
    ..We investigated the effect of an NRTI backbone in individuals receiving PI/r after failing NNRTI-based combined antiretroviral therapy...
  24. doi request reprint Clinical epidemiology of HIV-associated end-stage renal failure in the UK
    Loveleen Bansi
    University College London Medical School, London, UK
    AIDS 23:2517-21. 2009
    ..To describe the clinical epidemiology of HIV-associated end-stage renal failure (HIV/ESRF) from 1998 to 2007 in the United Kingdom...
  25. doi request reprint Outcome in renal Al amyloidosis after chemotherapy
    Jennifer H Pinney
    National Amyloidosis Centre, Division of Medicine, University College London Medical School, Rowland Hill St, London NW3 2PF, United Kingdom
    J Clin Oncol 29:674-81. 2011
    ..The purpose of this study was to evaluate the effect of chemotherapy on clinical outcome among patients with renal AL amyloidosis...